Navigation Links
Cephalon Exceeds Both Sales and Earnings Guidance for Second Quarter of 2008
Date:7/29/2008

4,128)

Accumulated other comprehensive income 170,647 148,703

Total stockholders' equity 1,458,946 1,302,067

$3,456,889 $3,506,269

CEPHALON, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

Six Months Ended

June 30,

2008 2007

CASH FLOWS FROM OPERATING ACTIVITIES:

Net income $ 98,919 $ 70,877

Adjustments to reconcile net

income to net cash provided

by operating activities:

Deferred income tax expense (benefit) (2,603) 9,490

Shortfall tax benefits from

stock-based compensation - (198)

Depreciation and amortization 84,006 63,441

Stock-based compensation expense 21,894 24,627

Gain on sale of investment - (5,791)

Loss on disposals of property

and equipment 1,031 -

Other (418) 120

Changes in operating assets

and liabilities:

Receivables (56,210) (32,715)

Inventory (7,933) (26,009)

Other assets (24,027) (15,945)

Accounts payable, accrued

expenses and deferred revenues (10,427) 14,716

Other liabilities
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 Deep Knowledge Ventures last ... on ‘Commercialising Longevity Research’ and welcomed a host ... London Bioscience Innovation Center for the event, organised ... Analytics Ltd. The meeting highlighted the need for ... for age-related disease, as well as the crucial ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Robert Harman, DVM, ... Medicine company, is proud to announce the relaunch of his ... with a new series called “ What are Stem Cells ... an honest and straightforward foundation in the basics of stem ... decision on the right type of treatment when considering regenerative ...
(Date:7/10/2014)... 10, 2014  Franciscan St. Anthony Health-Crown ... for respiratory monitoring outside the operating room, ... in embracing state-of-the-art patient safety technology. ... breathing and can alert medical caregivers when ... amount of carbon dioxide the patient is ...
(Date:7/10/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/s3bqj2/photonic ... "International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, ... report to their offering. ... photonic integration traces its roots in the latter ... photonic integration went unexplored and unfulfilled for several ...
Breaking Biology Technology:DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2
... Robotic cars attracted attention last decade with a 100-mile driverless ... put up by the U.S. government. The past ... microrobots, miniaturized mobile machines designed to perform specific tasks. And ... some think the time has come for a microrobotics challenge. ...
... CASTRES, France , July 2, 2010 Olivier ... Pierre Fabre,Group starting September 1, 2010 . , ... Until now, Olivier Bohuon , 51, ... such, he ran the,group,s entire pharmaceutical activities from Chicago ( $22 ...
... ... progenitors into specific T cell lineages to the activity of a single gene encoding a ... for the development of blood cells lineages. , ... (PRWeb UK) July 1, 2010 -- A research team in Japan has ...
Cached Biology Technology:Thermal-powered, insect-like robot crawls into microrobot contenders' ring 2Thermal-powered, insect-like robot crawls into microrobot contenders' ring 3Olivier Bohuon Joins Pierre Fabre 2The Last Checkpoint to T Cell Fate 2
(Date:7/11/2014)... available in German . ... that uses the refraction of X-rays through a specimen ... with this method are often of much higher quality ... team of Prof. Franz Pfeiffer are particularly interested in ... including X-ray phase-contrast imaging. One main goal is ...
(Date:7/11/2014)... at the National Institute of Standards and Technology ... work more effectively, they often prove that necessity ... the case recently for M. Lorna De Leoz ... growing specialization of glycomics. Glycomics is the study ... that are attached to proteins and lipids and ...
(Date:7/11/2014)... 2014, Shenzhen, China Researchers from Salk Institute for ... first time evaluated the safety and reliability of ... developed a new method, TALEN-HDAdV, which could significantly ... cell (hiPSC). This study published online in ... foundation for stem cell-based gene therapy. , The ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2A new genome editing method brings the possibility of gene therapies closer to reality 2
... Health (NIMH), part of the National Institutes of Health, ... social behavior in humans--one of the most important but ... reported in Nature Neuroscience, published online on July 10, ... volunteers to those with a genetic abnormality, Williams Syndrome, ...
... Academy of Sciences (CAS) and the Danish Committee of ... release of pig genomic sequences. The released sequence data ... different domestic pig breeds from Europe and China. The ... genome sequencing effort, the Sino-Danish Pig Genome Project, started ...
... truckers and college students pulling all-nighters, appears to do ... is one of several in a new study that ... the modulation of sleep, wake, and arousal states. , ... colleagues at The Neurosciences Institute in San Diego. , ...
Cached Biology News:Scientists uncover new clues about brain function in human behavior 2Scientists uncover new clues about brain function in human behavior 3‘Blue Brain?project explores thought at molecular level 2